Sino Biopharm

News

Boehringer Ingelheim is paying $358m upfront for options on up to six antibody-drug conjugates and T-cell engagers from China's Sino Biopharma.

News

AstraZeneca has licensed a drug candidate for COPD from China's Sino Bio, which could compete with MSD's Ohtuvayre, in a deal valued at up to $2.1bn.

News

GSK has partnered Sino Biopharm to make the most of the Chinese launch of hepatitis B drug bepirovirsen, currently under NMPA review.

News

This week's round-up of pharma licensing deals features alliances involving Tenaya Therapeutics, Sino Bio, Antengene, and A2A Pharma.

News

LaNova Medicines is being bought out by minority shareholder Sino Biopharm in a deal valued at around $951 million.